Molecular mechanisms of human IRE1 activation through dimerization and ligand binding

Oncotarget

Volumn 6, Issue 15, 2015, Pages 13019-13035

  Joshi, Amar ^a   Newbatt, Yvette ^b   McAndrew, P Craig ^b   Stubbs, Mark ^b   Burke, Rosemary ^b   Richards, Mark W ^a   Bhatia, Chitra ^a   Caldwell, John J ^b   McHardy, Tatiana ^b   Collins, Ian ^b   Bayliss, Richard ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Drug discovery; Kinase; RNase; UPR

Indexed keywords

4 (IMIDAZO[1,2 B]PYRIDAZIN 3 YL)BENZAMIDE DERIVATIVE; NEK7 PROTEIN; PROTEIN IRE1; PROTEIN SERINE THREONINE KINASE; RIBONUCLEASE; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1; ERN1 PROTEIN, HUMAN; LIGAND; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIMERIZATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; IC50; LIGAND BINDING; MUTATION; NONHUMAN; PROTEIN DOMAIN; RNA SPLICING; SF9 CELL LINE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DEVELOPMENT; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; MOLECULAR MODEL; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; STRUCTURE ACTIVITY RELATION;

DRUG DISCOVERY; ENDORIBONUCLEASES; HUMANS; LIGANDS; MODELS, MOLECULAR; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN MULTIMERIZATION; PROTEIN-SERINE-THREONINE KINASES; RIBONUCLEASES; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 84931089936     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3864     Document Type: Article

References (44)

1. Walter, P. and D. Ron, The unfolded protein response: from stress pathway to homeostatic regulation. Science, 2011. 334: p. 1081-6.
2. Ron, D. and P. Walter, Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol, 2007. 8: p. 519-29.
3. Sidrauski, C. and P. Walter, The transmembrane kinase Ire1p is a site-specific endonuclease that initiates mRNA splicing in the unfolded protein response. Cell, 1997. 90: p. 1031-9.
4. Cox, J.S., C.E. Shamu, and P. Walter, Transcriptional induction of genes encoding endoplasmic reticulum resident proteins requires a transmembrane protein kinase. Cell, 1993. 73: p. 1197-206.
5. Shamu, C.E. and P. Walter, Oligomerization and phosphorylation of the Ire1p kinase during intracellular signaling from the endoplasmic reticulum to the nucleus. EMBO J, 1996. 15: p. 3028-39.
6. Yoshida, H., et al., XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell, 2001. 107: p. 881-91.
7. Gonzalez, T.N., et al., Mechanism of non-spliceosomal mRNA splicing in the unfolded protein response pathway. EMBO J, 1999. 18: p. 3119-32.
8. Kaser, A., et al., XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell, 2008. 134: p. 743-56.
9. Cao, S.S. and R.J. Kaufman, Targeting endoplasmic reticulum stress in metabolic disease. Expert Opin Ther Targets, 2013. 17: p. 437-48.
10. Carrasco, D.R., et al., The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell, 2007. 11: p. 349-60.
11. Chen, X., et al., XBP1 promotes triple-negative breast cancer by controlling the HIF1alpha pathway. Nature, 2014. 508: p. 103-7.
12. Wang, L., et al., Divergent allosteric control of the IRE1alpha endoribonuclease using kinase inhibitors. Nat Chem Biol, 2012. 8: p. 982-9.
13. Volkmann, K., et al., Potent and selective inhibitors of the inositol-requiring enzyme 1 endoribonuclease. J Biol Chem, 2011. 286: p. 12743-55.
14. Papandreou, I., et al., Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood, 2011. 117: p. 1311-4.
15. Cross, B.C., et al., The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1- binding small molecule. Proc Natl Acad Sci U S A, 2012. 109: p. E869-78.
16. Mimura, N., et al., Blockade of XBP1 splicing by inhibition of IRE1alpha is a promising therapeutic option in multiple myeloma. Blood, 2012. 119: p. 5772-81.
17. Prischi, F., et al., Phosphoregulation of Ire1 RNase splicing activity. Nat Commun, 2014. 5: p. 3554.
18. Korennykh, A.V., et al., The unfolded protein response signals through high-order assembly of Ire1. Nature, 2009. 457: p. 687-93.
19. Papa, F.R., et al., Bypassing a kinase activity with an ATPcompetitive drug. Science, 2003. 302: p. 1533-7.
20. Lee, K.P., et al., Structure of the dual enzyme Ire1 reveals the basis for catalysis and regulation in nonconventional RNA splicing. Cell, 2008. 132: p. 89-100.
21. Wiseman, R.L., et al., Flavonol activation defines an unanticipated ligand-binding site in the kinase-RNase domain of IRE1. Mol Cell, 2010. 38: p. 291-304.
22. Ali, M.M., et al., Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response. EMBO J, 2011. 30: p. 894-905.
23. Kornev, A.P., et al., Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc Natl Acad Sci U S A, 2006. 103: p. 17783-8.
24. Sanches, M., et al., Structure and mechanism of action of the hydroxy-aryl-aldehyde class of IRE1 endoribonuclease inhibitors. Nat Commun, 2014. 5: p. 4202.
25. Korennykh, A. and P. Walter, Structural basis of the unfolded protein response. Annu Rev Cell Dev Biol, 2012. 28: p. 251-77.
26. Harrington PE, B.K., Malwitz D, Tasker AS, Mohr C, Andrews KL, Dellamaggiore K, Kendall R, Beckmann H, Jaeckel P, Materna-Reichelt S, Allen JR, Lipford JR, Unfolded Protein Response in Cancer: IRE1 Inhibition by Selective Kinase Ligands Does Not Impair Tumor Cell Viability. ACS Med. Chem. Lett., 2014.
27. Richards, M.W., et al., An autoinhibitory tyrosine motif in the cell-cycle-regulated Nek7 kinase is released through binding of Nek9. Mol Cell, 2009. 36(4): p. 560-70.
28. Bayliss, R., et al., On the molecular mechanisms of mitotic kinase activation. Open Biol, 2012. 2: 120136.
29. Newbatt, Y., et al., Identification of autophosphorylation inhibitors of the inositol-requiring enzyme 1 alpha (IRE1alpha) by high-throughput screening using a DELFIA assay. J Biomol Screen, 2013. 18: p. 298-308.
30. Stanovnik B, T.M., Drnovšek I, 3-Bromoimidazo [1,2-b] pyridazine-bromine and 3-Bromo-6-chloroimidazo [1,2-b] pyridazine-bromine complexes; new brominating agents for organic compounds. . Synthesis, 1981. 1981: p. 987-89.
31. Itzhak, D., et al., Multiple autophosphorylations significantly enhance the endoribonuclease activity of human inositol requiring enzyme 1alpha. BMC Biochem, 2014. 15: p. 3.
32. Huang, H., et al., Dimeric structure of pseudokinase RNase L bound to 2-5A reveals a basis for interferon-induced antiviral activity. Mol Cell, 2014. 53: p. 221-34.
33. Han, Y., et al., Structure of human RNase L reveals the basis for regulated RNA decay in the IFN response. Science, 2014. 343: p. 1244-8.
34. Dodson, C.A., et al., A kinetic test characterizes kinase intramolecular and intermolecular autophosphorylation mechanisms. Sci Signal, 2013. 6: p. ra54.
35. Kabsch, W., Xds. Acta Crystallogr D Biol Crystallogr, 2010. 66: p. 125-32.
36. Evans, P.R. and G.N. Murshudov, How good are my data and what is the resolution? Acta Crystallogr D Biol Crystallogr, 2013. 69: p. 1204-14.
37. Winn, M.D., et al., Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr, 2011. 67: p. 235-42.
38. McCoy, A.J., et al., Phaser crystallographic software. J Appl Crystallogr, 2007. 40: p. 658-674.
39. Emsley, P., et al., Features and development of Coot. Acta Crystallogr D Biol Crystallogr, 2010. 66: p. 486-501.
40. Blanc, E., et al., Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT. Acta Crystallogr D Biol Crystallogr, 2004. 60: p. 2210-21.
41. Smart, O.S., et al., Exploiting structure similarity in refinement: automated NCS and target-structure restraints in BUSTER. Acta Crystallogr D Biol Crystallogr, 2012. 68:p. 368-80.
42. Ho, B.K. and F. Gruswitz, HOLLOW: generating accurate representations of channel and interior surfaces in molecular structures. BMC Struct Biol, 2008. 8: p. 49.
43. Laskowski, R.A. and M.B. Swindells, LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model, 2011. 51: p. 2778-86.
44. Schrodinger, LLC, The PyMOL Molecular Graphics System, Version 1.3r1. 2010.